SG11201706223VA - Biomarkers for pancreatic cancer - Google Patents
Biomarkers for pancreatic cancerInfo
- Publication number
- SG11201706223VA SG11201706223VA SG11201706223VA SG11201706223VA SG11201706223VA SG 11201706223V A SG11201706223V A SG 11201706223VA SG 11201706223V A SG11201706223V A SG 11201706223VA SG 11201706223V A SG11201706223V A SG 11201706223VA SG 11201706223V A SG11201706223V A SG 11201706223VA
- Authority
- SG
- Singapore
- Prior art keywords
- biomarkers
- pancreatic cancer
- pancreatic
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1501930.0A GB201501930D0 (en) | 2015-02-05 | 2015-02-05 | Biomarkers for pancreatic cancer |
| PCT/GB2016/050277 WO2016124947A1 (en) | 2015-02-05 | 2016-02-05 | Biomarkers for pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706223VA true SG11201706223VA (en) | 2017-08-30 |
Family
ID=52746188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706223VA SG11201706223VA (en) | 2015-02-05 | 2016-02-05 | Biomarkers for pancreatic cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10782301B2 (en) |
| EP (1) | EP3254111A1 (en) |
| JP (1) | JP6786499B2 (en) |
| KR (1) | KR102569984B1 (en) |
| CN (1) | CN107533062B (en) |
| AU (1) | AU2016214140B2 (en) |
| BR (1) | BR112017016808A2 (en) |
| CA (1) | CA2974775C (en) |
| CL (1) | CL2017001972A1 (en) |
| GB (1) | GB201501930D0 (en) |
| HK (1) | HK1247276A1 (en) |
| IL (1) | IL253710B (en) |
| MX (1) | MX2017009998A (en) |
| SG (1) | SG11201706223VA (en) |
| WO (1) | WO2016124947A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10782301B2 (en) | 2015-02-05 | 2020-09-22 | Queen Mary University Of London | Biomarkers for pancreatic cancer |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101680896A (en) | 2007-03-27 | 2010-03-24 | 伊缪诺维亚公司 | Method, array and use thereof |
| GB201517028D0 (en) * | 2015-09-25 | 2015-11-11 | Univ London Queen Mary | Novel biomarkers for pancreatic cancer |
| CN107674884A (en) * | 2017-09-05 | 2018-02-09 | 上海速创诊断产品有限公司 | It is a kind of to be used to detect pancreatic cancer marker REG1A biotinylation liposome and its preparation method and application |
| TWI643869B (en) * | 2017-12-14 | 2018-12-11 | 國立高雄大學 | Molecular extension printing material and preparation method thereof, magnetic molecular extension printing material and preparation method thereof |
| US20210052231A1 (en) * | 2017-12-14 | 2021-02-25 | Salcit Technologies Private Limited | Method and system for analyzing risk associated with respiratory sounds |
| KR102000387B1 (en) * | 2018-02-13 | 2019-07-15 | 서울대학교산학협력단 | Protein biomarkers for distinguishing malignancy of intraductal papillary mucinous neoplasm and their use |
| CN109358055A (en) * | 2018-12-18 | 2019-02-19 | 沈阳理工大学 | Enhanced sensitivity measures the mixed indicator test paper of ammonia and its preparation and detection method in air |
| CN111303281A (en) * | 2019-05-14 | 2020-06-19 | 长春恒晓生物科技有限责任公司 | Method for preparing pancreatic stone protein antibody and establishing and detecting PSP |
| GB202010970D0 (en) * | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| CN113248609B (en) * | 2021-07-14 | 2021-09-10 | 深圳市盛波尔生命科学技术有限责任公司 | Antibody combination for regenerated islet-derived protein 1alpha and detection kit comprising same |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9827228D0 (en) | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
| US7601826B2 (en) | 2002-09-30 | 2009-10-13 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human pancreatic cancers |
| AU2003900747A0 (en) | 2003-02-18 | 2003-03-06 | Garvan Institute Of Medical Research | Diagnosis and treatment of pancreatic cancer |
| US20050095611A1 (en) | 2003-05-02 | 2005-05-05 | Chan Daniel W. | Identification of biomarkers for detecting pancreatic cancer |
| WO2004102188A1 (en) | 2003-05-15 | 2004-11-25 | Europroteome Ag | Methods and applications of biomarker profiles in the diagnosis and treatment of breast cancer |
| DE102004042822A1 (en) | 2004-08-31 | 2006-03-16 | Technische Universität Dresden | Compounds and methods of treatment, diagnosis and prognosis in pancreatic diseases |
| EP1842065B1 (en) | 2005-01-28 | 2010-12-01 | Children's Medical Center Corporation | Methods for diagnosis and prognosis of bladder cancer |
| CA2617755A1 (en) | 2005-06-27 | 2007-01-04 | John Wayne Cancer Institute | Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome |
| WO2007035684A2 (en) | 2005-09-16 | 2007-03-29 | Primera Biosystems, Inc. | Method for quantitative detection of short rna molecules |
| EP2586455B1 (en) | 2006-01-05 | 2014-06-25 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
| AU2007217861A1 (en) | 2006-02-17 | 2007-08-30 | Children's Medical Center Corporation | Free NGAL as a biomarker for cancer |
| US20070231822A1 (en) | 2006-02-28 | 2007-10-04 | Michael Mitas | Methods for the detection and treatment of cancer |
| CA2664383C (en) | 2006-09-19 | 2017-08-22 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| EP2084539A4 (en) * | 2006-10-03 | 2010-09-08 | Neuren Pharmaceuticals Ltd | Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same |
| WO2008063479A2 (en) | 2006-11-17 | 2008-05-29 | Fred Hutchinson Cancer Research Center | Pancreatic cancer biomarkers |
| EP2610347B1 (en) | 2007-04-30 | 2015-04-15 | The Ohio State University Research Foundation | Methods of determining the prognosis of a subject with pancreatic cancer |
| EP2607497B1 (en) | 2008-05-12 | 2014-10-01 | Genomic Health, Inc. | Tests to predict responsiveness of cancer patients to chemotherapy treatment options |
| WO2009147530A2 (en) * | 2008-06-06 | 2009-12-10 | Neuren Pharmaceuticals Ltd | Conformation specific antibodies that bind trefoil factors |
| JP2012100536A (en) * | 2009-03-02 | 2012-05-31 | Genescience Co Ltd | Genetic testing method for cancer by analysis of expression of cancer-relating gene utilizing monocyte contained in blood sample |
| WO2011090492A1 (en) | 2010-01-19 | 2011-07-28 | Immunomedics, Inc. | Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
| EP2415877A3 (en) * | 2010-02-17 | 2012-02-15 | Deutsches Krebsforschungszentrum | Means and methods for diagnosing pancreatic cancer |
| WO2011137288A2 (en) | 2010-04-30 | 2011-11-03 | The Ohio State University | Mirna networks in cancers and leukemias and uses thereof |
| WO2012100339A1 (en) * | 2011-01-27 | 2012-08-02 | University Health Network | Methods and compositions for the detection of pancreatic cancer |
| US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
| WO2013043644A1 (en) * | 2011-09-21 | 2013-03-28 | The University Of North Carolina At Chapel Hill | Methods using liver disease biomarkers |
| DE102012204366B4 (en) | 2011-12-16 | 2017-07-27 | Siemens Aktiengesellschaft | Method and kit for identifying and quantifying a single-stranded target nucleic acid |
| WO2013106844A2 (en) * | 2012-01-13 | 2013-07-18 | Oncocyte Corporation | Methods and compositions for the treatment and diaginosis of pancreatic cancer |
| US20150011414A1 (en) | 2012-01-16 | 2015-01-08 | Herlev Hospital | Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples |
| US20130216545A1 (en) * | 2012-02-19 | 2013-08-22 | Claresa Levetan | Early Diagnosis and Novel Treatment of Cancer |
| WO2013152989A2 (en) * | 2012-04-10 | 2013-10-17 | Eth Zurich | Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer |
| US20130317083A1 (en) | 2012-05-04 | 2013-11-28 | Thomas Jefferson University | Non-coding transcripts for determination of cellular states |
| US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| US20140271621A1 (en) | 2013-03-14 | 2014-09-18 | Abbott Laboratories | Methods of prognosis and diagnosis of pancreatic cancer |
| US20150018230A1 (en) | 2013-06-11 | 2015-01-15 | Indiana University Research And Technology Corp. | PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA |
| GB201501930D0 (en) | 2015-02-05 | 2015-03-25 | Univ London Queen Mary | Biomarkers for pancreatic cancer |
| GB201517028D0 (en) | 2015-09-25 | 2015-11-11 | Univ London Queen Mary | Novel biomarkers for pancreatic cancer |
-
2015
- 2015-02-05 GB GBGB1501930.0A patent/GB201501930D0/en not_active Ceased
-
2016
- 2016-02-05 MX MX2017009998A patent/MX2017009998A/en unknown
- 2016-02-05 JP JP2017541693A patent/JP6786499B2/en active Active
- 2016-02-05 WO PCT/GB2016/050277 patent/WO2016124947A1/en active Application Filing
- 2016-02-05 CN CN201680018784.8A patent/CN107533062B/en active Active
- 2016-02-05 US US15/548,240 patent/US10782301B2/en active Active
- 2016-02-05 CA CA2974775A patent/CA2974775C/en active Active
- 2016-02-05 KR KR1020177024461A patent/KR102569984B1/en active IP Right Grant
- 2016-02-05 BR BR112017016808A patent/BR112017016808A2/en not_active Application Discontinuation
- 2016-02-05 EP EP16703840.5A patent/EP3254111A1/en active Pending
- 2016-02-05 SG SG11201706223VA patent/SG11201706223VA/en unknown
- 2016-02-05 AU AU2016214140A patent/AU2016214140B2/en active Active
-
2017
- 2017-07-28 IL IL253710A patent/IL253710B/en active IP Right Grant
- 2017-08-02 CL CL2017001972A patent/CL2017001972A1/en unknown
-
2018
- 2018-05-17 HK HK18106404.7A patent/HK1247276A1/en unknown
-
2020
- 2020-08-26 US US17/003,139 patent/US11977077B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10782301B2 (en) | 2015-02-05 | 2020-09-22 | Queen Mary University Of London | Biomarkers for pancreatic cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107533062A (en) | 2018-01-02 |
| GB201501930D0 (en) | 2015-03-25 |
| US20220042998A1 (en) | 2022-02-10 |
| CN107533062B (en) | 2021-03-23 |
| AU2016214140B2 (en) | 2021-11-04 |
| CL2017001972A1 (en) | 2018-03-23 |
| BR112017016808A2 (en) | 2018-04-03 |
| KR20170129118A (en) | 2017-11-24 |
| CA2974775C (en) | 2023-11-07 |
| US10782301B2 (en) | 2020-09-22 |
| IL253710A0 (en) | 2017-09-28 |
| HK1247276A1 (en) | 2018-09-21 |
| IL253710B (en) | 2020-08-31 |
| MX2017009998A (en) | 2018-02-01 |
| AU2016214140A1 (en) | 2017-08-17 |
| WO2016124947A1 (en) | 2016-08-11 |
| US11977077B2 (en) | 2024-05-07 |
| EP3254111A1 (en) | 2017-12-13 |
| US20190204323A1 (en) | 2019-07-04 |
| KR102569984B1 (en) | 2023-08-22 |
| JP6786499B2 (en) | 2020-11-18 |
| CA2974775A1 (en) | 2016-08-11 |
| JP2018504609A (en) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1247276A1 (en) | Biomarkers for pancreatic cancer | |
| GB2566681B (en) | Biomarker | |
| SG10202007262PA (en) | Copanlisib biomarkers | |
| SG10202007322PA (en) | Copanlisib biomarkers | |
| SG10202110526WA (en) | Biomarkers for cancer therapeutics | |
| GB201614455D0 (en) | Biomarkers | |
| GB201500584D0 (en) | Cancer biomarkers | |
| HK1245120A1 (en) | Novel therapies for cancer | |
| PT3198034T (en) | Biomarkers for cervical cancer. | |
| ZA201705532B (en) | Biomarkers for preeclampsia | |
| ZA202001821B (en) | Biomarker | |
| GB201710858D0 (en) | Biomarker | |
| HK1250257A1 (en) | Biomarker combinations for prostate disease | |
| GB201500729D0 (en) | Novel Biomarkers | |
| GB201517028D0 (en) | Novel biomarkers for pancreatic cancer | |
| HK1249134A1 (en) | Biomarkers for colorectal cancer related diseases | |
| IL259661A (en) | Biomarkers for treating cancer with apilimod | |
| GB201512133D0 (en) | Biomarkers | |
| GB201703641D0 (en) | Cancer biomarkers | |
| GB201707113D0 (en) | Biomarker | |
| GB201506666D0 (en) | Biomarkers for prostate cancer | |
| GB201519704D0 (en) | Biomarkers | |
| GB201521446D0 (en) | Biomarker | |
| GB201513683D0 (en) | Biomarkers | |
| GB201517081D0 (en) | Predicting increased risk for sporadic cancer |